SEARCH:   Advanced

Blood, 15 February 2008, Vol. 111, No. 4, pp. 2230-2237. Prepublished online as a Blood First Edition Paper on November 15, 2007; DOI 10.1182/blood-2007-07-100115. This Article Full Text Full Text (PDF) Supplemental Methods, Tables and Figure All Versions of this Article: blood-2007-07-100115v1 111/4/2230    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Chen, L. Articles by Shipp, M. A. Search for Related Content PubMed PubMed Citation Articles by Chen, L. Articles by Shipp, M. A. Related Collections Neoplasia Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  NEOPLASIA SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma Linfeng Chen1, Stefano Monti2, Przemyslaw Juszczynski1, John Daley1, Wen Chen1, Thomas E. Witzig3, Thomas M. Habermann3, Jeffery L. Kutok4, and Margaret A. Shipp1 1 Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; 2 Broad Institute, Cambridge, MA; 3 Mayo Clinic, Rochester, MN; and 4 Department of Pathology, Brigham and Women's Hospital, Boston, MA The role of B-cell receptor (BCR)–mediated survival signals in diffuse large B-cell lymphoma (DLBCL) remains undefined. Ligand-induced BCR signaling induces receptor oligomerization, Ig/β immunoreceptor tyrosine-based activation motif (ITAM) phosphorylation, and activation of the spleen tyrosine kinase (SYK), which initiates downstream events and amplifies the initial BCR signal. BCRs also transmit low-level tonic survival signals in the absence of receptor engagement. Herein, we assess the role of SYK-dependent tonic BCR survival signals in DLBCL cell lines and primary tumors and evaluate the efficacy of an ATP-competitive inhibitor of SYK, R406, in vitro. R406 induced apoptosis of the majority of examined DLBCL cell lines. In R406-sensitive DLBCL cell lines, R406 specifically inhibited both tonic- and ligand-induced BCR signaling (autophosphorylation of SYK525/526 and SYK-dependent phosphorylation of the B-cell linker protein [BLNK]). The majority of examined primary DLBCLs also exhibited tonic- and ligand-induced BCR signaling; in these primary tumors, BCR signaling was also inhibited by R406. Of note, BCR-dependent and R406-sensitive DLBCL cell lines were independently identified as "BCR-type" tumors by transcriptional profiling. Therefore, SYK-dependent tonic BCR signaling is an important and potentially targetable survival pathway in some, but not all, DLBCLs. In addition, R406-sensitive DLBCLs can be identified by their transcriptional profiles. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: M. R. McKeller, R. S. Robetorye, P. L. M. Dahia, and R. C. T. Aguiar Integrity of the CBL gene in mature B-cell malignancies Blood, November 5, 2009; 114(19): 4321 - 4322. [Full Text] [PDF] J. A. Burger, P. Ghia, A. Rosenwald, and F. Caligaris-Cappio The microenvironment in mature B-cell malignancies: a target for new treatment strategies Blood, October 15, 2009; 114(16): 3367 - 3375. [Abstract] [Full Text] [PDF] G. P. Coffey, R. Rajapaksa, R. Liu, O. Sharpe, C.-C. Kuo, S. W. Krauss, Y. Sagi, R. E. Davis, L. M. Staudt, J. P. Sharman, et al. Engagement of CD81 induces ezrin tyrosine phosphorylation and its cellular redistribution with filamentous actin J. Cell Sci., September 1, 2009; 122(17): 3137 - 3144. [Abstract] [Full Text] [PDF] M. P. Quiroga, K. Balakrishnan, A. V. Kurtova, M. Sivina, M. J. Keating, W. G. Wierda, V. Gandhi, and J. A. Burger B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406 Blood, July 30, 2009; 114(5): 1029 - 1037. [Abstract] [Full Text] [PDF] M. Buchner, S. Fuchs, G. Prinz, D. Pfeifer, K. Bartholome, M. Burger, N. Chevalier, L. Vallat, J. Timmer, J. G. Gribben, et al. Spleen Tyrosine Kinase Is Overexpressed and Represents a Potential Therapeutic Target in Chronic Lymphocytic Leukemia Cancer Res., July 1, 2009; 69(13): 5424 - 5432. [Abstract] [Full Text] [PDF] C. Li, S.-W. Kim, D. Rai, A. R. Bolla, S. Adhvaryu, M. C. Kinney, R. S. Robetorye, and R. C. T. Aguiar Copy number abnormalities, MYC activity, and the genetic fingerprint of normal B cells mechanistically define the microRNA profile of diffuse large B-cell lymphoma Blood, June 25, 2009; 113(26): 6681 - 6690. [Abstract] [Full Text] [PDF] S.-W. Kim, D. Rai, M. R. McKeller, and R. C. T. Aguiar Rational combined targeting of phosphodiesterase 4B and SYK in DLBCL Blood, June 11, 2009; 113(24): 6153 - 6160. [Abstract] [Full Text] [PDF] X. Zhang, U. Shrikhande, B. M. Alicie, Q. Zhou, and R. L. Geahlen Role of the Protein Tyrosine Kinase Syk in Regulating Cell-Cell Adhesion and Motility in Breast Cancer Cells Mol. Cancer Res., May 1, 2009; 7(5): 634 - 644. [Abstract] [Full Text] [PDF] R. P. Gobert, M. van den Eijnden, C. Szyndralewiez, C. Jorand-Lebrun, D. Swinnen, L. Chen, C. Gillieron, F. Pixley, P. Juillard, P. Gerber, et al. GLEPP1/Protein-tyrosine Phosphatase {phi} Inhibitors Block Chemotaxis in Vitro and in Vivo and Improve Murine Ulcerative Colitis J. Biol. Chem., April 24, 2009; 284(17): 11385 - 11395. [Abstract] [Full Text] [PDF] A. Podolanczuk, A. H. Lazarus, A. R. Crow, E. Grossbard, and J. B. Bussel Of mice and men: an open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of Syk Blood, April 2, 2009; 113(14): 3154 - 3160. [Abstract] [Full Text] [PDF] J. A. Burger, M. P. Quiroga, E. Hartmann, A. Burkle, W. G. Wierda, M. J. Keating, and A. Rosenwald High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation Blood, March 26, 2009; 113(13): 3050 - 3058. [Abstract] [Full Text] [PDF] R. M. Young, I. R. Hardy, R. L. Clarke, N. Lundy, P. Pine, B. C. Turner, T. A. Potter, and Y. Refaeli Mouse models of non-Hodgkin lymphoma reveal Syk as an important therapeutic target Blood, March 12, 2009; 113(11): 2508 - 2516. [Abstract] [Full Text] [PDF] J. Mori, A. C. Pearce, J. C. Spalton, B. Grygielska, J. A. Eble, M. G. Tomlinson, Y. A. Senis, and S. P. Watson G6b-B Inhibits Constitutive and Agonist-induced Signaling by Glycoprotein VI and CLEC-2 J. Biol. Chem., December 19, 2008; 283(51): 35419 - 35427. [Abstract] [Full Text] [PDF] R. Sud and J. W. Friedberg Salvage therapy for relapsed or refractory diffuse large B-cell lymphoma: impact of prior rituximab Haematologica, December 1, 2008; 93(12): 1776 - 1780. [Full Text] [PDF]

	Copyright © 2008 by American Society of Hematology         Online ISSN: 1528-0020